Sable Bio
The company provides an AI-powered platform called Sable Target Intelligence designed for toxicologists in the biotech and pharmaceutical industries. The software unifies safety data from clinical, genetic, experimental, and literature sources to help teams prioritize and mitigate toxicology risks. It enables users to evaluate drug target safety systematically, replacing static reports with up-to-date data to reduce bottlenecks in the assessment process.
Visit websiteLondon, UK
Software
Healthcare
Biotechnology
Artificial Intelligence
Funding summary
- Total raised
- €4.9M
- Funding rounds
- 2
Investors in Sable Bio
Investors on record for Sable Bio. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Sable Bio?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors